Michael Marberger
Overview
Explore the profile of Michael Marberger including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
145
Citations
3904
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
11.
Marberger M
Adv Ther
. 2013 Apr;
30(4):309-19.
PMID: 23584673
With the high prevalence of bothersome lower urinary tract symptoms (LUTS) in older men, clinical management has to be fairly simple and straightforward. In the absence of severe problems requiring...
12.
Klingler C, Margreiter M, Marberger M
Arch Esp Urol
. 2013 Feb;
66(1):79-89.
PMID: 23406803
Solid renal tumours with a diameter <4cm comprise up to half of all renal tumours coming for a therapeutic decision in tertiary care centres today. ∼80% are renal cell cancers,...
13.
Fullhase C, Chapple C, Cornu J, De Nunzio C, Gratzke C, Kaplan S, et al.
Eur Urol
. 2013 Feb;
64(2):228-43.
PMID: 23375241
Background: Several drugs are approved for the treatment of lower urinary tract symptoms (LUTS) in men, but these are mostly used by clinicians as monotherapies. The combination of different compounds,...
14.
Marberger M, Chartier-Kastler E, Egerdie B, Lee K, Grosse J, Bugarin D, et al.
Eur Urol
. 2012 Oct;
63(3):496-503.
PMID: 23098762
Background: Botulinum toxin treatment has been investigated as a minimally invasive alternative to oral medications in men with lower urinary tract symptoms (LUTS) suggestive of benign prostatic hyperplasia (LUTS/BPH). Objective:...
15.
Hansen J, Auprich M, Ahyai S, De La Taille A, van Poppel H, Marberger M, et al.
Eur Urol
. 2012 Aug;
63(2):201-9.
PMID: 22854248
Background: Urinary prostate cancer antigen 3 (PCA3) assay in combination with established clinical risk factors improves the identification of men at risk of harboring prostate cancer (PCa) at initial biopsy...
16.
Cordeiro E, Cathelineau X, Thuroff S, Marberger M, Crouzet S, de la Rosette J
BJU Int
. 2012 Jun;
110(9):1228-42.
PMID: 22672199
Unlabelled: What's known on the subject? and What does the study add? Novel therapeutic methods have emerged in recent years as 'focal' treatment alternatives in which cancer foci can be...
17.
Klatte T, Streubel B, Wrba F, Remzi M, Krammer B, de Martino M, et al.
Am J Clin Pathol
. 2012 Apr;
137(5):761-8.
PMID: 22523215
We studied the characteristics and prognosis of renal cell carcinoma (RCC) associated with Xp11.2 translocation and transcription factor E3 (TFE3) expression and determined the need for genetic analysis in routine...
18.
Smeenge M, Barentsz J, Cosgrove D, de la Rosette J, de Reijke T, Eggener S, et al.
BJU Int
. 2012 Apr;
110(7):942-8.
PMID: 22462566
What's known on the subject? and What does the study add? Focal therapy techniques are emerging in prostate cancer treatment. However, several key questions about patient selection, treatment and monitoring...
19.
Marberger M, Barentsz J, Emberton M, Hugosson J, Loeb S, Klotz L, et al.
BJU Int
. 2012 Jan;
109 Suppl 2:1-7.
PMID: 22257098
The reported incidence of prostate cancer has risen since the implementation of screening. It is felt that the introduction of widespread prostate-specific antigen testing is responsible for most patients with...
20.
van Poppel H, Haese A, Graefen M, De La Taille A, Irani J, de Reijke T, et al.
BJU Int
. 2011 Sep;
109(3):360-6.
PMID: 21883822
Objective: To evaluate the relationship between Prostate CAncer gene 3 (PCA3) and prostate cancer significance. Patients And Methods: Clinical data from two multi-centre European open-label, prospective studies evaluating the clinical...